Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin.
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Nitazoxanide (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms STEALTHC-2
- 30 May 2012 Actual end date Feb 2010 added as reported by ClinicalTrials.gov.
- 30 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Apr 2010 Final results were presented as a late-breaker at the 45th Annual Meeting of the European Association for the Study of the Liver.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History